Biotechnology

Landfar

Landfar released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 119.3 M, actual EPS CNY 0.0336

Landfar to Release FY2025 Annual Earnings on April 29, 2026, Pre-Market BJT

Landfar to Release FY2026 Q1 Earnings on April 29 After-Market (BJT)

Landfar released FY2025 Annual Earnings on April 14 Pre-Market (BJT), with actual revenue of CNY 415.94 M and EPS of CNY 0.09

Landfar released FY2025 Q4 earnings on April 14 Pre-Market (BJT), actual revenue CNY 332.5 M, actual EPS CNY 0.0802

Landfar released FY2025 Q3 earnings on October 26 After-Market BJT, actual revenue CNY 31.85 M, actual EPS CNY 0.0264

Landfar released FY2025 9 Months Earnings on October 26 After-Market BJT, actual revenue CNY 83.44 M, actual EPS CNY 0.0158

Landfar FY2025 Q3 Earnings Release on October 27 After-Market BJT

Landfar released FY2025 Semi-Annual Earnings on August 27 After-Market (BJT), with actual revenue of CNY 51.59 M and EPS of CNY -0.0106

Landfar released FY2025 Q2 earnings on August 27 After-Market (BJT), actual revenue CNY 29.14 M, actual EPS CNY -0.0038

Landfar to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT)

*ST Biology Maintains C-Level ESG Rating

Nanhua Biological Announces 2024 Annual Report

Nanhua Bio Independent Director Submits 2024 Annual Report

Landfar released FY2024 Q4 earnings on April 28 After-Market (BJT), actual revenue CNY 42.03 M, actual EPS CNY -0.0342

Landfar released FY2025 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 22.45 M, actual EPS CNY -0.0067

Landfar released FY2024 Annual Earnings on April 28 After-Market BJT, with actual revenue of CNY 134.45 M and EPS of CNY -0.06

Nanhu Biological 2024 Earnings Forecast Shifts from Profit to Loss

Landfar Bio-medicine FY2025 Q1 Earnings Release on April 29 After-Market BJT

Landfar Bio-medicine FY2024 Earnings Release Scheduled for April 29, 2025 After-Market BJT

The Global Luminex Multiplex Assays Market is projected to grow from USD 1.82 billion in 2025 to USD 3.89 billion by 2033, at a CAGR of 10.0%. This growth is driven by the rising demand for high-throughput biomarker profiling and standardized testing workflows. Key factors include the efficiency of multiplex systems, regulatory support for standardized panels, and the expansion of outsourced research models. However, challenges such as validation complexity and elevated costs may impact adoption rates.

fidelity

Luminex Multiplex Assays Market Projected to Reach USD 3.89 Billion by 2033, Driven by Rising Demand for High-Throughput Biomarker Profiling and Standardized Multiplex Testing Workflows: Verified Market Research

000504

Landfar plans to acquire 51% equity of Hunan Huize Pharmaceutical in cash, which is expected to constitute a major asset reorganization. After the transaction, Huize Pharmaceutical will become a subsidiary and be included in the consolidated financial statements. Huize Pharmaceutical focuses on drug research and development as well as clinical evaluation, providing pharmaceutical research, clinical trials, and other services. This acquisition aims to enhance the profitability and risk resistance of the biopharmaceutical sector and improve the company's operational efficiency

Zhitong

ST Landfar plans to acquire 51% equity of Huize Pharmaceutical, which is expected to constitute a significant asset restructuring situation

300001

On July 10th, a total of 4 listed companies had their restricted shares unlocked, with a total market value of approximately 1.973 billion yuan. The specific situation of the restricted share unlocks today is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlocking Shares NanHua Biological 000504 Additional A Shares Original Shareholder Allocation Listing 18.4492 million TGOOD 300001 Equity Incentive Restricted Circulation 4.5561 million Weike Technology 301196 Pre-issue Shares Restricted Circulation 56.9 million Tiancheng Technology 688603 7.267 million

TGOOD

Overview of the lifting of restrictions on the sale of A-shares | July 10

ST Landfar announced plans to list the sale of its 52% equity stake in Nanhua Peace Hospital Management (Hunan) Co., Ltd. on the Hunan United Property Rights Exchange. This move aims to adjust and optimize the business structure, with the listing price referencing relevant assessment conclusions and not being lower than the assessed value, taking into account factors such as the transfer of control over the target assets

ST Landfar plans to list the sale of a 52% stake in its subsidiary Nanhua Heping

002620

688287

002305

002713

The ST sector strengthened, with *ST GUANDIAN rising over 6%, and more than 20 stocks including *ST LANGOLD, ST RUIHE, *ST DYRS, and *ST Landfar hitting the daily limit

Ruihe Decoration

GUANDIAN DEFENSE

LANGOLD

DYRS

The ST sector strengthened, with over 20 stocks hitting the daily limit up

According to the announcement from Landfar Bio-medicine, the company expects its net profit for the fiscal year 2024 and net profit after deducting non-recurring gains and losses to both be negative, and the operating income after deduction is expected to be below 300 million yuan. According to Article 9.3.1 (1) of the Shenzhen Stock Exchange Stock Listing Rules, after the disclosure of the company's 2024 annual report, the trading of the company's stock may be subject to delisting risk warning (the stock abbreviation will be prefixed with "*ST")

Landfar Bio-medicine: The company's stock trading may be subject to delisting risk warning

Landfar Bio-medicine released a revised performance forecast for 2024, expecting a net loss of 19 million to 21 million yuan. The company originally expected a net profit of 12.5 million to 15.5 million yuan

Landfar Bio-medicine revised its 2024 performance forecast, expecting a net loss of 19 million to 21 million yuan

On the 21st, a seminar on the development of the cell industry in Hunan Province was held in Changsha. At the meeting, representatives from 9 companies including Landfar Bio-medicine, Yuantai Bio, Guangxiu High-tech, Yuanpin Cell, Siweikang Pharmaceutical, Yunshang Cell, Xuzhi Bio, Junuo Cell, and Bizu Bio, along with representatives from industrial parks such as Hunan Xiangjiang New Area, and relevant provincial departments such as the Provincial Development and Reform Commission, provided suggestions based on actual conditions, covering aspects such as industrial foundation, innovation capability, policy support, talent aggregation, and international layout

Hunan Province held a seminar on the development of the cell industry

Landfar Bio-medicine expects a net profit of 12.5 million to 15.5 million yuan for the fiscal year 2024, turning a profit compared to the previous year. The improvement in performance is mainly attributed to a decrease in financial costs, an increase in the profitability of the cell business, and a rise in revenue from self-operated beauty products and other agency sales

HUIJIE

Hbmc

Huazhi Digital Media

Estee Lauder

Proya

Landfar Bio-medicine expects to turn a profit, with a projected net profit of 12.5 million to 15.5 million yuan for the fiscal year 2024, compared to a loss in the previous year

300238

Today, stem cell concept stocks opened with fluctuations. On the news front, on January 2nd, the National Medical Products Administration conditionally approved the listing of the first stem cell therapy drug in China, Aimi Maitosai Injection, through a priority review and approval process, for the treatment of acute graft-versus-host disease (aGVHD) primarily affecting the digestive tract in patients over 14 years old who have failed hormone therapy. In this regard, reporters contacted Zhongyuan Union, Guanhao Biotech, and Landfar Bio-medicine regarding their stem cell business. Staff from Guanhao Biotech and Landfar Bio-medicine stated that the company mainly involves stem cell storage and currently has no stem cell therapy drugs

USHK News

Guanhao Biotech

Hengrui Pharma

VCANBIO

Lifeon Pharmaceutical

SH PHARMA

TIBET AIM PHARM

SSY GROUP

TY PHAR.

SHYNDEC

China Meheco

China's first stem cell therapy drug is on the market! Multiple listed companies respond

Landfar(000504.SZ)